Keefe, S. M., Hoffman-Censits, J., Cohen, R. B., Eliasof, S., Garmey, E. G., Gunnarsson, O., … Haas, N. B. (2015). HIF inhibition in metastatic renal cell carcinoma (RCC): FINAL results from a phase 1-2a clinical trial evaluating the nanoparticle-drug conjugate, CRLX101, in combination with bevacizumab. In BJU INTERNATIONAL (Vol. 116, pp. 10–11).

Keefe, Stephen M., Jean Hoffman-Censits, Roger B. Cohen, Scott Eliasof, Edward G. Garmey, Orvar Gunnarsson, Meliessa Hennessy, et al. “HIF inhibition in metastatic renal cell carcinoma (RCC): FINAL results from a phase 1-2a clinical trial evaluating the nanoparticle-drug conjugate, CRLX101, in combination with bevacizumab.” In BJU INTERNATIONAL, 116:10–11, 2015.

Keefe SM, Hoffman-Censits J, Cohen RB, Eliasof S, Garmey EG, Gunnarsson O, et al. HIF inhibition in metastatic renal cell carcinoma (RCC): FINAL results from a phase 1-2a clinical trial evaluating the nanoparticle-drug conjugate, CRLX101, in combination with bevacizumab. In: BJU INTERNATIONAL. 2015. p. 10–1.

Keefe, Stephen M., et al. “HIF inhibition in metastatic renal cell carcinoma (RCC): FINAL results from a phase 1-2a clinical trial evaluating the nanoparticle-drug conjugate, CRLX101, in combination with bevacizumab.” BJU INTERNATIONAL, vol. 116, 2015, pp. 10–11.

Keefe SM, Hoffman-Censits J, Cohen RB, Eliasof S, Garmey EG, Gunnarsson O, Hennessy M, Jayaraman L, Mamtani R, Mannan AM, Nixon AB, Piscitelli A, Robinson J, Smith A, Tellez AB, Vaughn D, Walicki M, Haas NB. HIF inhibition in metastatic renal cell carcinoma (RCC): FINAL results from a phase 1-2a clinical trial evaluating the nanoparticle-drug conjugate, CRLX101, in combination with bevacizumab. BJU INTERNATIONAL. 2015. p. 10–11.